Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII
- PMID: 670391
- PMCID: PMC371757
- DOI: 10.1172/JCI109120
Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII
Abstract
Radiolabeled human Factor VIII was used to study its survival in normals and patients with classic hemophilia, and to study the heterogeneity of Factor VIII; Purified Factor VIII was radiolabeled with 125iodine (125I-VIII) without loss of its structural integrity. The survival of 125I-VIII was studied in six normals and six hemophiliacs of whom four of the hemophiliacs had received transfusions with normal cryoprecipitate before the 125I-VIII infusion. No significant difference was observed between the disappearance of Factor VIII coagulant activity and radioactivity in these hemophiliacs. 125I-VIII in plasma showed a biphasic disappearance with an average t1/2 of 2.9 +/- 0.4 h (SEM) for the first phase and 18.6 +/- 0.7 h (SEM) for the second phase, respectively. The survival of 125I-VIII was similar comparing normals and hemophiliacs. The highest molecular weight forms of Factor VIII disappear more rapidly than the lower molecular weight ones. This was established by analysis of the fractions obtained by gel chromatography of plasma collected at several times after infusion and by analysis of the in vivo disappearance of three subfractions of Factor VIII. The fraction of 125I-VIII binding to platelets in the presence of ristocetin (containing the highest molecular weight forms of Factor VIII including the ristocetin cofactor) represented about 50% of the radioactivity present in plasma after infusion and showed a t 1/2 of 11.7 +/- 0.9 h (SEM) for the second phase. The fraction, which was recovered in cryoprecipitate of the recipient's plasma, represented about 90% of the initial radioactivity and showed a t 1/2 of 16.3 +/- 0.8 h (SEM) for the second phase. The fraction of 125I-VIII remaining in the cryosupernatant plasma (containing low molecular weight forms of Factor (VIII) showed a t 1/2 of 27.2 +/- 1.1 h (SEM). The first phase of the disappearance of 125I-VIII is caused in part by the disappearance of the highest molecular weight forms, which are possibly removed by the reticuloendothelial system.
Similar articles
-
Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate.J Lab Clin Med. 1978 Jan;91(1):32-46. J Lab Clin Med. 1978. PMID: 618989
-
Heterogeneity of human factor VIII. III. Transitions between forms of factor VIII present in cryoprecipitate and in cryosupernatant plasma.J Lab Clin Med. 1980 Mar;95(3):323-34. J Lab Clin Med. 1980. PMID: 7354239
-
Heterogeneity of human factor VIII. II. Characterization of forms of factor VIII binding to platelets in the presence of ristocetin.J Lab Clin Med. 1978 Jul;92(1):96-107. J Lab Clin Med. 1978. PMID: 659967 No abstract available.
-
Survival of iodine-125-labeled factor VIII in patients with von Willebrand's disease.J Lab Clin Med. 1981 Mar;97(3):332-44. J Lab Clin Med. 1981. PMID: 6780640 No abstract available.
-
Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.J Clin Invest. 1973 Nov;52(11):2697-707. doi: 10.1172/JCI107464. J Clin Invest. 1973. PMID: 4201262 Free PMC article.
Cited by
-
Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.J Pharm Sci. 2015 Feb;104(2):388-95. doi: 10.1002/jps.23963. Epub 2014 Apr 2. J Pharm Sci. 2015. PMID: 24700333 Free PMC article.
-
FVIII half-life extension by coadministration of a D'D3 albumin fusion protein in mice, rabbits, rats, and monkeys.Blood Adv. 2020 May 12;4(9):1870-1880. doi: 10.1182/bloodadvances.2019000999. Blood Adv. 2020. PMID: 32374879 Free PMC article.
-
Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III.J Clin Invest. 1985 Feb;75(2):531-40. doi: 10.1172/JCI111729. J Clin Invest. 1985. PMID: 3919060 Free PMC article.
-
Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.Ann Hematol. 1991 Sep;63(3):155-65. doi: 10.1007/BF01703248. Ann Hematol. 1991. PMID: 1932292 Review. No abstract available.
-
Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies.Clin Pharmacokinet. 1992 May;22(5):385-95. doi: 10.2165/00003088-199222050-00005. Clin Pharmacokinet. 1992. PMID: 1505144
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources